Literature DB >> 32228541

Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data.

Annika Steffen1, Julia Nübel2, Frank Jacobi3, Jörg Bätzing4, Jakob Holstiege4.   

Abstract

BACKGROUND: Depression is frequently accompanied by other mental disorders and various somatic diseases; however, previous comorbidity studies often relied on self-reported data and have not simultaneously assessed the entire spectrum of mental and somatic diagnoses. The aim is to provide a complete picture of mental and somatic comorbidity of depression in routine outpatient care in a high income country with a relatively well equipped health care system.
METHODS: Using ambulatory claims data covering 87% of the German population (age 15+), we designed a cross-sectional study by identifying persons diagnosed with mild, moderate and severe depression in 2017 (N = 6.3 million) and a control group matched 4:1 on sex, 5-year age group and region of residence (N = 25.2 million). Stratified by severity, we calculated the prevalence of 202 diagnosis groups included in the ICD-10 in persons with depression as compared to matched controls using prevalence ratios (PR).
RESULTS: Nearly all mental disorders were at least twice as prevalent in persons with depression relative to controls, showing a dose-response relationship with depression severity. Irrespective of severity, the three most prevalent somatic comorbid diagnosis groups were 'other dorsopathies' (M50-M54), 'hypertensive diseases' (I10-I15) and 'metabolic disorders' (E70-E90), exhibiting PRs in moderate depression of 1.56, 1.23 and 1.33, respectively. Strong associations were revealed with diseases of the central nervous system (i.e. multiple sclerosis) and several neurological diseases, among them sleep disorders, migraine and epilepsy, most of them exhibiting at least 2- to 3-fold higher prevalences in depression relative to controls. Utilization of health care was higher among depression cases compared to controls.
CONCLUSIONS: The present study based on data from nearly the complete adolescent and adult population in Germany comprehensively illustrates the comorbidity status of persons diagnosed with depression as coded in routine health care. Our study should contribute to increasing the awareness of the strong interconnection of depression with all other mental and the vast majority of somatic diseases. Our findings underscore clinical and health-economic relevance and the necessity of systematically addressing the high comorbidity of depression and somatic as well as other mental diseases through prevention, early identification and adequate management of depressive symptoms.

Entities:  

Keywords:  Ambulatory claims data; Comorbidity; Depression; Mental disorders; Somatic diseases

Year:  2020        PMID: 32228541     DOI: 10.1186/s12888-020-02546-8

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  24 in total

1.  Acceptability of a technology-supported and solution-focused intervention (DIALOG+) for chronic depression: views of service users and clinicians.

Authors:  Aleksandra Matanov; Philip McNamee; Syeda Akther; Nick Barber; Victoria Bird
Journal:  BMC Psychiatry       Date:  2021-05-20       Impact factor: 3.630

2.  Network analysis of internet addiction and depression among Chinese college students during the COVID-19 pandemic: A longitudinal study.

Authors:  Yue Zhao; Diyang Qu; Shiyun Chen; Xinli Chi
Journal:  Comput Human Behav       Date:  2022-08-05

Review 3.  Guided Internet-Delivered Treatment for Depression: Scoping Review.

Authors:  Line Børtveit; Anders Dechsling; Stefan Sütterlin; Tine Nordgreen; Anders Nordahl-Hansen
Journal:  JMIR Ment Health       Date:  2022-10-04

4.  Nature and Extent of Physical Comorbidities Among Korean Patients With Mental Illnesses: Pairwise and Network Analysis Based on Health Insurance Claims Data.

Authors:  Ho Joon Kim; Sam Yi Shin; Seong Hoon Jeong
Journal:  Psychiatry Investig       Date:  2022-06-15       Impact factor: 3.202

5.  Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior.

Authors:  Adam Wojtas; Agnieszka Bysiek; Agnieszka Wawrzczak-Bargiela; Zuzanna Szych; Iwona Majcher-Maślanka; Monika Herian; Marzena Maćkowiak; Krystyna Gołembiowska
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

6.  Parsing between- and within-person effects: Longitudinal associations between irritability and internalizing and externalizing problems from early childhood through adolescence.

Authors:  Emma Chad-Friedman; Maria M Galano; Edward P Lemay; Thomas M Olino; Daniel N Klein; Lea R Dougherty
Journal:  Dev Psychopathol       Date:  2021-12-27

Review 7.  7T ultra-high-field neuroimaging for mental health: an emerging tool for precision psychiatry?

Authors:  Irene Neuner; Tanja Veselinović; Shukti Ramkiran; Ravichandran Rajkumar; Gereon Johannes Schnellbaecher; N Jon Shah
Journal:  Transl Psychiatry       Date:  2022-01-26       Impact factor: 7.989

Review 8.  Psychedelics and Other Psychoplastogens for Treating Mental Illness.

Authors:  Maxemiliano V Vargas; Retsina Meyer; Arabo A Avanes; Mark Rus; David E Olson
Journal:  Front Psychiatry       Date:  2021-10-04       Impact factor: 4.157

9.  Quality assessment of a consultation-liaison psychiatry service.

Authors:  Zoltan Kovacs; Marton Asztalos; Simon Grøntved; René Ernst Nielsen
Journal:  BMC Psychiatry       Date:  2021-06-01       Impact factor: 3.630

10.  Phenotypic Disease Network Analysis to Identify Comorbidity Patterns in Hospitalized Patients with Ischemic Heart Disease Using Large-Scale Administrative Data.

Authors:  Dejia Zhou; Liya Wang; Shuhan Ding; Minghui Shen; Hang Qiu
Journal:  Healthcare (Basel)       Date:  2022-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.